Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

The 2014 US biotech IPO market in 10 charts

616 views

Published on

The IPO class of 2014 hit new benchmarks in terms of both the number of public listings (63) and proceeds raised (US$4.9 billion), outstripping the superlatives set in 2000-01 at the height of the genomics bubble. Forty-eight (76%) of the biotechs that debuted in 2014 garnered more than US$50 million in their initial offerings, while 17 (27%) cleared the US$100 million mark. Nearly 60% of new companies listed within or above their IPO ranges in 2014. As of 31 December 2014, 42% of the US biotechs that went public in 2014 were trading up relative to their initial offering prices.

To read more, go to the EY Life Sciences Vital Signs site: http://www.ey.com/GL/en/Industries/Life-Sciences/EY-vital-signs-2014-a-new-benchmark-year-for-biotech-ipos

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

The 2014 US biotech IPO market in 10 charts

  1. 1. in 10 charts Among the 58 therapeutic companies ... The 2014 US biotech IPO market Therapeutic | 58 Diagnostic | 5 Licensed | 26% Q2 Q3 Q4 Therapeutic Molecular diagnostic Retained rights | 74% Of the 63 IPOs, over 92% were therapeutic companies US biotechs in 2014 not only set a record for number of IPOs ... ... but also set a record for IPO proceeds, nearing US$5 billion Only 31% of therapeutic companies were in Phase III or later By 31 December, stocks were up by 42% relative to their IPO prices … Nearly 60% were priced within or above their expected ranges ... while only 26% had licensed their lead product to a larger company 26+74+J Oncology | 14 CNS | 7 Infection | 6 Renal | 6 Endocrinology | 5 Ophthalmic | 5 Other | 15 24% were primarily in oncology ... 24+12+10+10+9+9+26+J Phase II | 32 Phase I | 5 Pre-clinical | 3 Marketed | 3 Phase III | 15 ... 55% were in Phase II ... 55+26+5+5+9+J H1 H2 Compiled by EY Global Life Sciences Center (@EY_LifeSciences) using data from 28 years of EY biotechnology annual reports. For more data, trends and implications, download our thought leadership at ey.com/lifesciences or join the conversation on our blog (lifesciencesblog.ey.com). 92+8+J Phase III or marketed Phase II or earlier Within or above Below range Q1 2000 52 412013 2005 17 282004 242006 222007 2014 63 2014 $4.9b 2000 $4.5b 2013 $3.3b 2004 $1.6b 2007 $1.2b 2006 $1.1b 2010 $1.1b Q2 Q3 Q4 34% 49% -33% 16% 70% 52% 43% 25%66% 75% 0% 0% 20% 20% -20% -40% 40% 40% 60% 60%80% … with therapeutic outperforming diagnostic Q1 73% 23 total IPOs 17 total IPOs 13 total IPOs 10 total IPOs 27% 38% 62% 54% 46% 60% 40%

×